Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

2

Revenue 2017

Novartis

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Novartis' 2013 sales performance.

Novartis

Roche’s Ocrevus shows significant benefit in early-stage MS patients

Roche’s Ocrevus shows significant benefit in early-stage MS patients

The early-stage data bolsters Ocrevus’ claim in the crowded MS market, particularly against Novartis’ Kesimpta (ofatumumab).

Novartis’ MS therapy Kesimpta reduces risk of disability progression regardless of relapses

Novartis’ MS therapy Kesimpta reduces risk of disability progression regardless of relapses The CD20 monoclonal antibody (mAb) was originally developed by Danish biotech company Genmab, and subsequently developed and marketed worldwide by Novartis under a licence agreement. ... According to Genmab, Kesimpta is the first B-cell therapy that can

CureVac outlines COVID-19 vaccine production plans ahead of regulatory approval

CureVac outlines COVID-19 vaccine production plans ahead of regulatory approval To support the planned rollout of its COVID-19 jab, CureVac has signed a number of strategic agreements, including with Novartis and Bayer. ... Novartis plans to manufacture the mRNA and bulk drug product of CureVac's CVnCoV for up to 50 million doses by

Novartis agrees to help produce Roche’s repurposed COVID-19 drug

Novartis agrees to help produce Roche’s repurposed COVID-19 drug Novartis will make ingredients for Actemra/RoActemra, which is being investigated in COVID-19. ... Novartis has signed an initial agreement with Roche to help produce its repurposed COVID-19 treatment Actemra/RoActemra.

BeiGene, Novartis’s PD-1 inhibitor tislelizumab hits the mark in second- or third-line NSCLC

BeiGene, Novartis’s PD-1 inhibitor tislelizumab hits the mark in second- or third-line NSCLC At 12 months, the PFS rate was 23.3% for patients receiving BeiGene/Novartis’ therapy versus 5.7% in the docetaxel arm. ... added. In January, Novartis and BeiGene signed a strategic collaboration agreement for the Swiss pharma company to in-license

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

DATA shutterstock_1818502577-640.jpg
Empowering patients empowers results
Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials...
Don’t limit diversity to just representation in clinical trials
What is the power of diversity in the healthcare environment? Can it make clinical trials more inclusive?...
Oh no… not more training
Paul Hutchings, founder of fox&cat, discusses ways to help your team manage pressure in a more human, pressure-centric and engaging way...

Infographics